UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of January, 2008

Commission File Number 0-30860

 

Axcan Pharma Inc.

(Exact Name of Registrant)

 

597, boul, Laurier, Mont-Saint-Hilaire (Québec), Canada J3H 6C4

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F o     Form 40-F x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7):

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o     No x

 

If “Yes” is marked, indicate the file number assigned to the registrant in connection with Rule 12g3-2(b):

82-

 

 

 


 

 

EXHIBITS

 

Exhibit No.

 

Description

 

 

 

 

 

99.1

 

January 14, 2008 Letter to Shareholders of Axcan Pharma Inc..

 

 

 

 

 

99.2

 

December 20, 2007 press release entitled “Axcan Pharma Inc. Obtains Interim Order for Proposed Arrangement and Announces Date of Special Shareholder Meeting.”

 

 

 

 

 

99.3

 

January 10, 2008 press release entitled “Axcan and TPG Capital Receive Antitrust Clearances in Connection with the Proposed Acquisition.”

 

 

 

 

 

99.4

 

January 10, 2008 press release entitled “ISS, Proxy Governance, Inc. and Glass, Lewis & Co. Recommend Shareholders Vote “For” the Proposed Acquisition of Axcan Pharma by an Affiliate of TPG Capital.”

 

 

 

2


 

 

 

SIGNATURES

 

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

AXCAN PHARMA INC.

 

  Date: January 14, 2008

By:

/s/ Richard Tarte

 

Name:

Richard Tarte

 

Title:

Vice President, Corporate Development

 

 

and General Counsel

 

 

3

 

Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Axcan Pharma (MM) Charts.
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Axcan Pharma (MM) Charts.